Logo image of RDY

DR. REDDY'S LABORATORIES-ADR (RDY) Stock Price, Forecast & Analysis

USA - New York Stock Exchange - NYSE:RDY - US2561352038 - ADR

13.28 USD
+0.34 (+2.63%)
Last: 1/21/2026, 4:02:15 PM
13.28 USD
0 (0%)
After Hours: 1/21/2026, 4:02:15 PM

RDY Key Statistics, Chart & Performance

Key Statistics
Market Cap11.06B
Revenue(TTM)343.10B
Net Income(TTM)57.72B
Shares832.52M
Float586.94M
52 Week High16.17
52 Week Low12.26
Yearly Dividend0.09
Dividend Yield0.5%
EPS(TTM)0.76
PE17.47
Fwd PE21.15
Earnings (Next)01-21
IPO1986-01-01
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
RDY short term performance overview.The bars show the price performance of RDY in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -2 -4 -6 -8 -10

RDY long term performance overview.The bars show the price performance of RDY in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20

The current stock price of RDY is 13.28 USD. In the past month the price decreased by -7.17%. In the past year, price decreased by -7.64%.

DR. REDDY'S LABORATORIES-ADR / RDY Daily stock chart

RDY Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

RDY Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to RDY. RDY scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RDY Financial Highlights

Over the last trailing twelve months RDY reported a non-GAAP Earnings per Share(EPS) of 0.76. The EPS increased by 8.21% compared to the year before.


Industry RankSector Rank
PM (TTM) 16.82%
ROA 10.62%
ROE 16.03%
Debt/Equity 0.03
Chartmill High Growth Momentum
EPS Q2Q%7.44%
Sales Q2Q%9.83%
EPS 1Y (TTM)8.21%
Revenue 1Y (TTM)14.04%

RDY Forecast & Estimates

45 analysts have analysed RDY and the average price target is 14.92 USD. This implies a price increase of 12.35% is expected in the next year compared to the current price of 13.28.

For the next year, analysts expect an EPS growth of -6.14% and a revenue growth 5.1% for RDY


Analysts
Analysts56.89
Price Target14.92 (12.35%)
EPS Next Y-6.14%
Revenue Next Year5.1%

RDY Ownership

Ownership
Inst Owners49.42%
Ins Owners1.23%
Short Float %2.1%
Short Ratio11.13

RDY Latest News, Press Relases and Analysis

About RDY

Company Profile

RDY logo image Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

Company Info

DR. REDDY'S LABORATORIES-ADR

8-2-337, Road No.3 Banjara Hills

Hyderabad TELANGANA 500-034 IN

CEO: Erez Israeli

Employees: 27048

RDY Company Website

RDY Investor Relations

Phone: 914049002900

DR. REDDY'S LABORATORIES-ADR / RDY FAQ

What does DR. REDDY'S LABORATORIES-ADR do?

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.


What is the stock price of DR. REDDY'S LABORATORIES-ADR today?

The current stock price of RDY is 13.28 USD. The price increased by 2.63% in the last trading session.


Does RDY stock pay dividends?

DR. REDDY'S LABORATORIES-ADR (RDY) has a dividend yield of 0.5%. The yearly dividend amount is currently 0.09.


How is the ChartMill rating for DR. REDDY'S LABORATORIES-ADR?

RDY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Can you provide the PE ratio for RDY stock?

The PE ratio for DR. REDDY'S LABORATORIES-ADR (RDY) is 17.47. This is based on the reported non-GAAP earnings per share of 0.76 and the current share price of 13.28 USD.


Can you provide the upcoming earnings date for DR. REDDY'S LABORATORIES-ADR?

DR. REDDY'S LABORATORIES-ADR (RDY) will report earnings on 2026-01-21.


What is the outstanding short interest for DR. REDDY'S LABORATORIES-ADR?

The outstanding short interest for DR. REDDY'S LABORATORIES-ADR (RDY) is 2.1% of its float.